Rapport Therapeutics (RAPP) Corporate presentation summary

Leadership and expertise

• Management and board have extensive neuroscience, biotech, and pharma experience, including former executives from Janssen, Lilly, Cerevel, and Alnylam.

• Leadership includes expertise in drug discovery, clinical development, finance, and corporate strategy.

Precision neuroscience platform and pipeline

• Focus on small molecule precision medicines for neurological and psychiatric disorders, leveraging receptor associated proteins (RAPs) for high selectivity.

• Lead program RAP-219 targets TARPy8, a forebrain-restricted AMPAR modulator, with robust Phase 2a data in drug-resistant focal onset seizures (FOS).

• Pipeline includes programs for primary generalized tonic-clonic seizures (PGTCS), bipolar mania, chronic pain, migraine, and hearing/vestibular disorders.

• RAP-219 has potential as a pipeline-in-a-product, with long-acting injectable (LAI) formulation in development.

Market opportunity and financials

• Large addressable markets: FOS (~$15B), PGTCS (~$7B), and bipolar mania (~$40B).

• RAP-219 exclusivity expected into late 2040s, with LAI formulation extending lifecycle.

• Strong financial position with $513M cash as of September 2025, funding operations into 2H 2029.